Kymera Therapeutics, Inc. announced that new KT-333 Phase 1 data highlighting safety, pharmacokinetics, pharmacodynamics and clinical responses will be presented at the ASH 65th Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego, California.
November 2, 2023
· 7 min read